E.A. van Schaick

Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model

Philippe Jacqmin, Eric Snoeck, E.A. van Schaick et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2006 · 160 citations

Systems Pharmacology, Therapeutic Drug Monitoring, Pharmacokinetic Modeling +14

Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo.

Piet H. van der Graaf, E.A. van Schaick, Sandra A. G. Visser et al. · PubMed · 1999 · 70 citations

Pharmacotherapy, Experimental Pharmacology, Physiologically-based Pharmacokinetic Modeling +17

Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats

E.A. van Schaick, Kenneth A. Jacobson, Hea O. Kim et al. · European Journal of Pharmacology · 1996 · 67 citations

Medicine, Hemodynamic Effects, Physiology +7

Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Effects of N6-Cyclopentyladenosine Analogs on Heart Rate in Rat: Estimation of in Vivo Operational Affinity and Efficacy at Adenosine A1 Receptors

Piet Hein Van der Graaf, E.A. van Schaick, Ron A. A. Mathôt et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 56 citations

Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat.

Ron A. A. Mathôt, E.A. van Schaick, M.W.E. Langemeijer et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 49 citations